Boehringer Ingelheim Starts Phase II Study of its Potential First-in-Class Oral Compound as a Treatment for Geographic Atrophy​

Boehringer Ingelheim today announces the start of the JADE Phase II clinical study (NCT06769048), investigating the efficacy and safety of BI 1584862 as a potential first-in-class treatment for geographic atrophy (GA).